Horan Capital Advisors. buys $2,901,990 stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Horan Capital Advisors. scooped up 458 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 25,593 shares of Celgene Corporation which is valued at $2,901,990.Celgene Corporation makes up approximately 2.22% of Horan Capital Advisors.’s portfolio.

Other Hedge Funds, Including , Edmond De Rothschild Holding S.a. boosted its stake in CELG in the latest quarter, The investment management firm added 10,195 additional shares and now holds a total of 254,172 shares of Celgene Corporation which is valued at $28,820,563. Celgene Corporation makes up approx 0.92% of Edmond De Rothschild Holding S.a.’s portfolio. Harel Insurance Investments Financial Services Ltd. added CELG to its portfolio by purchasing 2,692 company shares during the most recent quarter which is valued at $312,649. Celgene Corporation makes up approx 0.04% of Harel Insurance Investments Financial Services Ltd.’s portfolio.Baltimore-washington Financial Advisors boosted its stake in CELG in the latest quarter, The investment management firm added 1,665 additional shares and now holds a total of 29,759 shares of Celgene Corporation which is valued at $3,217,245. Celgene Corporation makes up approx 0.93% of Baltimore-washington Financial Advisors’s portfolio. Rothschild Capital Partners sold out all of its stake in CELG during the most recent quarter. The investment firm sold 2,000 shares of CELG which is valued $216,220.

Celgene Corporation opened for trading at $111.83 and hit $112.93 on the upside on Friday, eventually ending the session at $112.16, with a gain of 0.03% or 0.03 points. The heightened volatility saw the trading volume jump to 29,16,819 shares. Company has a market cap of $86,937 M.

On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.